166 related articles for article (PubMed ID: 12912941)
1. Pharmacokinetics and immunological aspects of a phase Ib study with intratumoral administration of recombinant human interleukin-12 in patients with head and neck squamous cell carcinoma: a decrease of T-bet in peripheral blood mononuclear cells.
Van Herpen CM; Huijbens R; Looman M; De Vries J; Marres H; Van De Ven J; Hermsen R; Adema GJ; De Mulder PH
Clin Cancer Res; 2003 Aug; 9(8):2950-6. PubMed ID: 12912941
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-helper 1 profile in the locoregional lymph nodes.
van Herpen CM; Looman M; Zonneveld M; Scharenborg N; de Wilde PC; van de Locht L; Merkx MA; Adema GJ; de Mulder PH
Clin Cancer Res; 2004 Apr; 10(8):2626-35. PubMed ID: 15102664
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor.
van Herpen CM; van der Laak JA; de Vries IJ; van Krieken JH; de Wilde PC; Balvers MG; Adema GJ; De Mulder PH
Clin Cancer Res; 2005 Mar; 11(5):1899-909. PubMed ID: 15756016
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
Lenzi R; Rosenblum M; Verschraegen C; Kudelka AP; Kavanagh JJ; Hicks ME; Lang EA; Nash MA; Levy LB; Garcia ME; Platsoucas CD; Abbruzzese JL; Freedman RS
Clin Cancer Res; 2002 Dec; 8(12):3686-95. PubMed ID: 12473577
[TBL] [Abstract][Full Text] [Related]
6. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma.
Peterson AC; Harlin H; Gajewski TF
J Clin Oncol; 2003 Jun; 21(12):2342-8. PubMed ID: 12805336
[TBL] [Abstract][Full Text] [Related]
7. A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies.
Ohno R; Yamaguchi Y; Toge T; Kinouchi T; Kotake T; Shibata M; Kiyohara Y; Ikeda S; Fukui I; Gohchi A; Sugiyama Y; Saji S; Hazama S; Oka M; Ohnishi K; Ohhashi Y; Tsukagoshi S; Taguchi T
Clin Cancer Res; 2000 Jul; 6(7):2661-9. PubMed ID: 10914707
[TBL] [Abstract][Full Text] [Related]
8. Immunological effects of interleukin 12 administered by bolus intravenous injection to patients with cancer.
Robertson MJ; Cameron C; Atkins MB; Gordon MS; Lotze MT; Sherman ML; Ritz J
Clin Cancer Res; 1999 Jan; 5(1):9-16. PubMed ID: 9918197
[TBL] [Abstract][Full Text] [Related]
9. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses.
Portielje JE; Lamers CH; Kruit WH; Sparreboom A; Bolhuis RL; Stoter G; Huber C; Gratama JW
Clin Cancer Res; 2003 Jan; 9(1):76-83. PubMed ID: 12538454
[TBL] [Abstract][Full Text] [Related]
10. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
O'Malley BW; Li D; McQuone SJ; Ralston R
Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
[TBL] [Abstract][Full Text] [Related]
11. The effect of leukocyte interleukin injection (Multikine) treatment on the peritumoral and intratumoral subpopulation of mononuclear cells and on tumor epithelia: a possible new approach to augmenting sensitivity to radiation therapy and chemotherapy in oral cancer--a multicenter phase I/II clinical Trial.
Tímár J; Forster-Horváth C; Lukits J; Döme B; Ladányi A; Remenár E; Kásler M; Bencsik M; Répássy G; Szabó G; Velich N; Suba Z; Elõ J; Balatoni Z; Bajtai A; Chretien P; Talor E
Laryngoscope; 2003 Dec; 113(12):2206-17. PubMed ID: 14660929
[TBL] [Abstract][Full Text] [Related]
12. Expression of IL-18 in patients with head and neck squamous cell carcinoma.
Riedel F; Adam S; Feick P; Haas S; Götte K; Hörmann K;
Int J Mol Med; 2004 Feb; 13(2):267-72. PubMed ID: 14719133
[TBL] [Abstract][Full Text] [Related]
13. A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C.
Zeuzem S; Hopf U; Carreno V; Diago M; Shiffman M; Grüne S; Dudley FJ; Rakhit A; Rittweger K; Yap SH; Koff RS; Thomas HC
Hepatology; 1999 Apr; 29(4):1280-7. PubMed ID: 10094976
[TBL] [Abstract][Full Text] [Related]
14. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
Robertson MJ; Mier JW; Logan T; Atkins M; Koon H; Koch KM; Kathman S; Pandite LN; Oei C; Kirby LC; Jewell RC; Bell WN; Thurmond LM; Weisenbach J; Roberts S; Dar MM
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4265-73. PubMed ID: 16857801
[TBL] [Abstract][Full Text] [Related]
15. Elevated gene expression of Th1/Th2 associated transcription factors is correlated with disease activity in patients with systemic lupus erythematosus.
Lit LC; Wong CK; Li EK; Tam LS; Lam CW; Lo YM
J Rheumatol; 2007 Jan; 34(1):89-96. PubMed ID: 17117487
[TBL] [Abstract][Full Text] [Related]
16. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides.
Duvic M; Sherman ML; Wood GS; Kuzel TM; Olsen E; Foss F; Laliberté RJ; Ryan JL; Zonno K; Rook AH
J Am Acad Dermatol; 2006 Nov; 55(5):807-13. PubMed ID: 17052486
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings.
Bukowski RM; Olencki T; Gunn H; McLain D; Budd GT; Sandstrom K; Tuason L; Redovan C; Rayman P; Tubbs R; Resta D; Elson P; Finke J
Clin Cancer Res; 1996 Feb; 2(2):347-57. PubMed ID: 9816178
[TBL] [Abstract][Full Text] [Related]
18. Antitumor and antiangiogenic effects of interleukin 12 gene therapy in murine head and neck carcinoma model.
Imagawa Y; Satake K; Kato Y; Tahara H; Tsukuda M
Auris Nasus Larynx; 2004 Sep; 31(3):239-45. PubMed ID: 15364358
[TBL] [Abstract][Full Text] [Related]
19. Intratumoral injection of dendritic cells engineered to secrete interleukin-12 by recombinant adenovirus in patients with metastatic gastrointestinal carcinomas.
Mazzolini G; Alfaro C; Sangro B; Feijoó E; Ruiz J; Benito A; Tirapu I; Arina A; Sola J; Herraiz M; Lucena F; Olagüe C; Subtil J; Quiroga J; Herrero I; Sádaba B; Bendandi M; Qian C; Prieto J; Melero I
J Clin Oncol; 2005 Feb; 23(5):999-1010. PubMed ID: 15598979
[TBL] [Abstract][Full Text] [Related]
20. Hypercytokinemia and hyperactivation of phospho-p38 mitogen-activated protein kinase in severe human influenza A virus infection.
Lee N; Wong CK; Chan PK; Lun SW; Lui G; Wong B; Hui DS; Lam CW; Cockram CS; Choi KW; Yeung AC; Tang JW; Sung JJ
Clin Infect Dis; 2007 Sep; 45(6):723-31. PubMed ID: 17712756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
